Umecrine Cognition is led by a team with extensive experience in drug development and commercialization, including leadership roles at AstraZeneca, Merck&Co, Medivir, Sobi (former Biovitrum), and Karo Bio.
The board comprises individuals with international experience in creating shareholder value in life‑science companies, bringing expertise in drug and business development, particularly in the US market. The company also collaborates with world‑leading medical experts who advise on clinical development programs.